Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2007-02-06
2007-02-06
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S094100, C514S006900, C534S016000, C435S183000
Reexamination Certificate
active
10866180
ABSTRACT:
The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac—, R1, R2and R3are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4and R5are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.
REFERENCES:
patent: 4735210 (1988-04-01), Goldenberg
patent: 4863713 (1989-09-01), Goodwin
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5256395 (1993-10-01), Barbet
patent: 5274076 (1993-12-01), Barbet
patent: 5328679 (1994-07-01), Hansen
patent: 5697902 (1997-12-01), Goldenberg
patent: 5746996 (1998-05-01), Govindan
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6071490 (2000-06-01), Griffiths et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6120768 (2000-09-01), Griffiths et al.
patent: 6126916 (2000-10-01), McBride et al.
patent: 6558669 (2003-05-01), Govindan et al.
patent: 6663866 (2003-12-01), Govindan
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7011816 (2006-03-01), Griffiths
patent: 7052872 (2006-05-01), Hansen et al.
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 2003/0026764 (2003-02-01), Griffiths
patent: 2003/0124057 (2003-07-01), Griffiths et al.
patent: 2003/0176784 (2003-09-01), Griffiths et al.
patent: 2003/0198595 (2003-10-01), Goldenberg et al.
patent: 2003/0220470 (2003-11-01), Govindan
patent: 2003/0235534 (2003-12-01), Griffiths et al.
patent: 2004/0022726 (2004-02-01), Goldenberg et al.
patent: 2004/0057902 (2004-03-01), Gold et al.
patent: 2004/0235065 (2004-11-01), Hansen et al.
patent: 2005/0014297 (2005-01-01), Nejad
patent: 2006/0104899 (2006-05-01), Hansen et al.
patent: WO 2004/029093 (2004-04-01), None
Barbet, J., et al., “Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA.TIMES ANTI—DTPA-Indium Bispecific Antibody,” J. Nucl. Med. 1998;39:1172-1178.
Boden et al., Preliminary Study of the Metal Binding Site of an Anti-DTPA-Indium Antibody by Equilibrium Binding Immunoassays and Imm Bioconjugate Chem., 6:373-379, (1995).
Gautherot, E., et al., “Therapy for Colon Carconoma Xenografts with Bi-Specific Antibody-Targeted, Iodine-131-Labeled Bivalent Hapten” Cancer Suppl. 1997; 80:2618-2623.
Gautherot, E., et al., “Radioimmunotherapy of LS174T Colon Carconoma in Nude Mice Using an Iodine-131-Labeled Bivalent Hapten Combined with an Anti-CEA. Times Anti-Indium-DTPA Bi-specific Antibody” J. Nucl. Med. Suppl. 1997; 38-.
Goodwin, D. A., et al., “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-labeled Bifunctional Haptens” J. Nucl. Med., 1988; 29:226-234.
Zoller, Margot, et al., “Establishment and Characterization of Monoclonal Antibodies Against an Octahedral Gallium Chelate Suitable for Immunoscintigraphy with PET,” J Nucl Med 1992: 33: 1366-1372 (1992).
Kranenborg, Marion H., et al., “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma” Cancer Research (Suppl.) 55, 5864-5867, Dec. 1, 1995.
Kranenborg, Marion, et al., “The Effect of Antibody Protein Dose of Anti-Renal Cell Carcinoma Monoclonal Antibodies in Nude Mice with Renal Cell Carcinoma Xenografts” Cancer (suppl.) 80:2390-2397 (1997).
Schuhmacher, Jochen et al., “Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission tomography” Cancer Res. 1995: 55, 115-123.
Sharkey, Robert M., “Development of a Streptavidiin—Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method for Radioimmunotherapy of Colorectal Cancer. Studies in a Human Colon Cancer Xenograft Model” Bioconjugate Chem. 1997, 8, 595-604.
Stickney, Dwight R., et al., “Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma” Cancer Research 51, 6650-6655, Dec. 15, 1991.
Goldenberg David M.
McBride William J.
Faegre & Benson LLP
Heard Thomas S.
Immunomedics Inc.
Tsang Cecilia J.
LandOfFree
D-amino acid peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with D-amino acid peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and D-amino acid peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887814